Patents by Inventor Michael Anthony Cawthorne

Michael Anthony Cawthorne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130245110
    Abstract: The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.
    Type: Application
    Filed: January 7, 2013
    Publication date: September 19, 2013
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Michael Anthony Cawthorne, Saoirse O'Sullivan
  • Publication number: 20130165446
    Abstract: The present invention addresses the problem of finding a compound having both PPAR activation activity and angiotensin receptor antagonistic activity. The present invention is a benzo- or pyrido-imidazole derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, or a ester or amide thereof (where A is biphenyl methyl-imidazolyl, biphenyl methyl-benzimidazolyl, or the like, B is divalent benzimidazolyl or the like, C is carboxyl or the like, E is divalent phenyl, naphthyl, or the like, G is a dangling bond, oxygen, or the like, Q is oxygen or sulfur, n is an integer from 1 to 6, p is an integer from 1 to 6, V is a dangling bond, oxygen, or the like, and R is hydrogen, alkyl, or the like).
    Type: Application
    Filed: May 11, 2011
    Publication date: June 27, 2013
    Inventors: Takashi Fujita, Hiroyoshi Horikoshi, Michael Anthony Cawthorne
  • Publication number: 20110082195
    Abstract: The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in increasing energy expenditure in a subject. Furthermore the CBD alone or in combination with another cannabinoid or the THCV alone or in combination with another cannabinoid are used as part of a regime to manage or treat type I or II diabetes, obesity, dyslipidaemia, related metabolic disorders and cardiovascular disease.
    Type: Application
    Filed: January 21, 2009
    Publication date: April 7, 2011
    Applicant: GW PHARMA LIMITED
    Inventors: Geoffrey Guy, Stephen Wright, Michael Anthony Cawthorne, Saoirse O'Sullivan
  • Patent number: 7662784
    Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction or body weight in a human or mammalian animal.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: February 16, 2010
    Assignee: Ipsen Pharma, S.A.S.
    Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
  • Patent number: 7416744
    Abstract: The invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: August 26, 2008
    Assignee: Conopco, Inc.
    Inventors: Ian Duncan Rubin, Jasjit Singh Bindra, Michael Anthony Cawthorne
  • Patent number: 7256174
    Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X by administering a therapeutically effective amount of a somatostatin agonist or a pharmaceutical composition comprised of a somatostatin agonist to a patient suffering from insulin resistance or Syndrome X.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: August 14, 2007
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
  • Patent number: 7033616
    Abstract: The invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: April 25, 2006
    Assignee: Phytopharm PLC
    Inventors: Ian Duncan Rubin, Jasjit Singh Bindra, Michael Anthony Cawthorne
  • Patent number: 7034003
    Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction of body weight in a human or mammalian animal.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: April 25, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
    Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
  • Patent number: 7026289
    Abstract: The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: April 11, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
    Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
  • Patent number: 6774109
    Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor (“SSTR-5”) and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyperamylinemia with a ligand selective for SSTR-5.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: August 10, 2004
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Simon Jon Dunmore, Michelle Davenport, Michael Anthony Cawthorne
  • Publication number: 20040146951
    Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor (“SSTR-5”) and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyperamylinemia with a ligand selective for SSTR-5.
    Type: Application
    Filed: January 8, 2004
    Publication date: July 29, 2004
    Inventors: Simon Jon Dunmore, Michelle Davenport, Michael Anthony Cawthorne
  • Publication number: 20040072734
    Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. The invention also includes pharmaceutical compositions comprising a somatostatin or somatostatin agonist and the use of such products in the preparation of such compositions.
    Type: Application
    Filed: February 18, 2003
    Publication date: April 15, 2004
    Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
  • Publication number: 20020151500
    Abstract: The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols. glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.
    Type: Application
    Filed: March 20, 2000
    Publication date: October 17, 2002
    Inventors: MICHAEL ANTHONY CAWTHORNE, YONG-LING LIU, MATTHEW V. SENNITT
  • Publication number: 20020146468
    Abstract: The invention relates inter alia to pharmaceutical compositions containing an extract obtainable from a plant of the genus Trichocaulon or Hoodia having anti-diabetic activity; and to the use of such extracts and to compound (1) as herein defined and its analogues for the manufacture of medicaments having anti-diabetic activity.
    Type: Application
    Filed: June 27, 2001
    Publication date: October 10, 2002
    Inventors: Ian Duncan Rubin, Jasjit Singh Bindra, Michael Anthony Cawthorne
  • Publication number: 20020042374
    Abstract: The present invention relates to a method of treating insulin resistance or syndrome X in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient.
    Type: Application
    Filed: May 13, 1998
    Publication date: April 11, 2002
    Inventors: MICHAEL ANTHONY CAWTHORNE, YONG-LING LIU, MATTHEW V. SENNITT
  • Publication number: 20010006790
    Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor (“SSTR-5”) and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyperamylinemia with a ligand selective for SSTR-5.
    Type: Application
    Filed: October 31, 1997
    Publication date: July 5, 2001
    Inventors: SIMON JON DUNMORE, MICHELLE DAVENPORT, MICHAEL ANTHONY CAWTHORNE
  • Patent number: 6004928
    Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to the patient.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: December 21, 1999
    Assignee: Biomeasure, Incorporated
    Inventors: Michael Anthony Cawthorne, Yong-Ling Liu, Matthew V. Sennitt
  • Patent number: 5763200
    Abstract: A method of determining the ability of a compound to both bind to somatostatin type-5 receptor ("SSTR-5") and inhibit amylin release. The method includes obtaining a preparation, either a cell preparation or a membrane preparation, which contains SSTR-5; incubating the preparation, the compound, and a SSTR-5 ligand, at least one of the ligand and the compound being detectably labeled; determining the ability of the compound to compete against the ligand for binding to SSTR-5; if and only if the compound is determined to be able to bind to SSTR-5, obtaining pancreatic cells; incubating the compound, the pancreatic cells, and an amylin release stimulator under conditions in which the amylin release stimulator would induce release of amylin from the pancreatic cells; and determining the ability of the compound to inhibit amylin release. Also disclosed is a method of treating hyper-amylinemia with a ligand selective for SSTR-5.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: June 9, 1998
    Assignee: Biomeasure, Incorporated
    Inventors: Simon Jon Dunmore, Michelle Davenport, Michael Anthony Cawthorne
  • Patent number: 4055635
    Abstract: Fibrinolytic pharmaceutical compositions are provided in unit dosage form and comprise a water-soluble complex of a proteolytic enzyme linked covalently to a polymeric substance.
    Type: Grant
    Filed: July 2, 1974
    Date of Patent: October 25, 1977
    Assignee: Beecham Group Limited
    Inventors: Joseph Green, Michael Anthony Cawthorne